David M. Holtzman

Oct 24, 2024 | onlinelibrary.wiley.com | Peter Lin |David M. Holtzman

CONFLICT OF INTEREST STATEMENT D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Cajal Neuroscience and consults for Asteroid. D.M.H. has a patent on the use of anti-ApoE antibodies that is licensed by Washington University to NextCure. REFERENCES 1, . Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019; 179(2): 312-339. 2, .

Oct 9, 2024 | jneurosci.org | Jason Rothman |David M. Holtzman |Claudia Figueroa-Romero |Gina Faraci

Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD? Joia K. Capocchi, Claudia Figueroa-Romero, Sage J. B. Dunham, Gina Faraci, Jason A. Rothman, Katrine L. Whiteson, Dong-oh Seo, David M. Holtzman, Stefanie Grabrucker, Yvonne M. Nolan, Rima Kaddurah-Daouk, David A. Jett Journal of Neuroscience 9 October 2024, 44 (41) e1295242024; DOI: 10.1523/JNEUROSCI.1295-24.2024

Sep 14, 2024 | cell.com | David M. Holtzman

KeywordsAlzheimer's diseasemicrogliaAPOEAPOE3chAPOE variantsAPOE-based therapiesAnti-amyloid therapies for AD: the end of the beginningAD is the most common human neurodegenerative disease and causes a considerable global health and financial burden [1].

Jul 2, 2024 | nature.com | Jingqin Luo |Erik D. Roberson |Carlos Cruchaga |David M. Holtzman |Randall J. Bateman

AbstractBlood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics’ PrecivityAD test for Aβ42 and Aβ40.

Jun 19, 2024 | nature.com | David M. Holtzman

AbstractAlzheimer’s disease (AD) is a complex, progressive primary neurodegenerative disease. Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) has remained the strongest single genome-wide associated risk variant in AD. Scientific advances in APOE biology, AD pathophysiology and ApoE-targeted therapies have brought APOE to the forefront of research, with potential translation into routine AD clinical care.